Genetic polymorphism in hOGG1 is associated with triple-negative breast cancer risk in Chinese Han women

Breast

Volumn 22, Issue 5, 2013, Pages 707-712

  Xie, Hui ^a,b   Xia, Kai ^b,c   Rong, Hui ^b   Chen, Xiaoxiang ^b,d  

^a WOMEN S HOSPITAL OF NANJING MEDICAL UNIVERSITY   (China)

^b NANJING MEDICAL UNIVERSITY   (China)

^c JIANGYIN PEOPLE S HOSPITAL   (China)

^d SOUTHEAST UNIVERSITY   (China)

Author keywords

Breast cancer; Genetic polymorphism; HOGG1 gene

Indexed keywords

8 HYDROXY 2' DEOXYGUANINE; CYTOSINE; GUANINE; GUANINE DERIVATIVE; PROTEIN P53; UNCLASSIFIED DRUG;

8 HYDROXYGUANINE GLYCOSYLASE 1 GENE; AGE; ARTICLE; BREAST CANCER; CANCER PATIENT; CANCER RISK; CHINESE; CONTROLLED STUDY; DNA DAMAGE; DNA REPAIR; FEMALE; GENE; GENOTYPE; HIGH RESOLUTION MELTING ANALYSIS; HOGG1 GENE; HUMAN; MAJOR CLINICAL STUDY; NUCLEIC ACID BASE SUBSTITUTION; OXIDATIVE STRESS; P53 POSITIVE BREAST CANCER; PREMENOPAUSE; PRIORITY JOURNAL; RISK ASSESSMENT; SEQUENCE ANALYSIS; SINGLE NUCLEOTIDE POLYMORPHISM; TRIPLE NEGATIVE BREAST CANCER;

BMI; BODY MASS INDEX; BREAST CANCER; CI; CONFIDENCE INTERVAL; GENETIC POLYMORPHISM; HIGH-RESOLUTION MELTING; HOGG1 GENE; HRM; ODDS RATIO; OR; SINGLE NUCLEOTIDE POLYMORPHISM; SNP; TNBC; TRIPLE-NEGATIVE BREAST CANCER;

ADULT; AGE FACTORS; ASIAN CONTINENTAL ANCESTRY GROUP; CARCINOMA, DUCTAL, BREAST; CARCINOMA, LOBULAR; CASE-CONTROL STUDIES; CHINA; DNA GLYCOSYLASES; FEMALE; GENOTYPE; HUMANS; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; PREMENOPAUSE; RISK FACTORS; SEQUENCE ANALYSIS, DNA; TRIPLE NEGATIVE BREAST NEOPLASMS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84884162599     PISSN: 09609776     EISSN: 15323080     Source Type: Journal    
DOI: 10.1016/j.breast.2012.12.016     Document Type: Article

References (56)

1. The global burden of disease 2008 update 2010, WHO, WHO Press, Geneva, Switzerland, [accessed 02.02.10.]. http://www.who.int/research/en/.
2. Jemal A., Center M.M., DeSantis C., Ward E.M. Global patterns of cancer incidence and mortality rates and trends. Cancer Epidemiol Biomarkers Prev 2010, 19:1893-1907.
3. Li J., Zhang B.N., Fan J.H., Pang Y., Zhang P., Wang S.L., et al. Anation-wide multicenter 10-year (1999-2008) retrospective clinical epidemiological study of female breast cancer in China. BMC Cancer 2011, 11:364.
4. Cuzick J. Epidemiology of breast cancer - selected highlights. Breast 2003, 12:405-411.
5. Spry M., Scott T., Pierce H., D'Orazio J.A. DNA repair pathways and hereditary cancer susceptibility syndromes. Front Biosci 2007, 12:4191-4207.
6. Barnham K.J., Masters C.L., Bush A.I. Neurodegenerative diseases and oxidative stress. Nat Rev Drug Discov 2004, 3:205-214.
7. Miyake H., Hara I., Kamidono S., Eto H. Oxidative DNA damage in patients with prostate cancer and its response to treatment. JUrol 2004, 171:1533-1536.
8. Diakowska D., Lewandowski A., Kopec W., Diakowski W., Chrzanowska T. Oxidative DNA damage and total antioxidant status in serum of patients with esophageal squamous cell carcinoma. Hepatogastroenterology 2007, 54:1701-1704.
9. Tanaka H., Fujita N., Sugimoto R., Urawa N., Horiike S., Kobayashi Y., et al. Hepatic oxidative DNA damage is associated with increased risk for hepatocellular carcinoma in chronic hepatitis C. Br J Cancer 2008, 98:580-586.
10. Robertson A.B., Klungland A., Rognes T., Leiros I. DNA repair in mammalian cells: base excision repair: the long and short of it. Cell Mol Life Sci 2009, 66:981-993.
11. Zharkov D.O. Base excision DNA repair. Cell Mol Life Sci 2008, 65:1544-1565.
12. Wu P.E., Shen C.Y. 'Hide-then-hit' to explain the importance of genotypic polymorphism of DNA repair genes in determining susceptibility to cancer. JMol Cell Biol 2011, 3:59-65.
13. Sangrajrang S., Schmezer P., Burkholder I., Waas P., Boffetta P., Brennan P., et al. Polymorphisms in three base excision repair genes and breast cancer risk in Thai women. Breast Cancer Res Treat 2008, 111:279-288.
14. Zhang Y., Newcomb P.A., Egan K.M., Titus-Ernstoff L., Chanock S., Welch R., et al. Genetic polymorphisms in base-excision repair pathway genes and risk of breast cancer. Cancer Epidemiol Biomarkers Prev 2006, 15:353-358.
15. Wei B., Zhou Y., Xu Z., Xi B., Cheng H., Ruan J., et al. The effect of hOGG1 Ser326Cys polymorphism on cancer risk: evidence from a meta-analysis. PLoS One 2011, 6:e27545.
16. Rossner P., Terry M.B., Gammon M.D., Zhang F.F., Teitelbaum S.L., Eng S.M., et al. OGG1 polymorphisms and breast cancer risk. Cancer Epidemiol Biomarkers Prev 2006, 15:811-815.
17. Xing D.Y., Tan W., Song N., Lin D.X. Ser326Cys polymorphism in hOGG1 gene and risk of esophageal cancer in a Chinese population. Int J Cancer 2001, 95:140-143.
18. Li Q., Huang L., Rong L., Xue Y., Lu Q., Rui Y., et al. hOGG1 Ser326Cys polymorphism and risk of childhood acute lymphoblastic leukemia in a Chinese population. Cancer Sci 2011, 102:1123-1127.
19. Canbay E., Cakmakoglu B., Zeybek U., Sozen S., Cacina C., Gulluoglu M., et al. Association of APE1 and hOGG1 polymorphisms with colorectal cancer risk in a Turkish population. Curr Med Res Opin 2011, 27:1295-1302.
20. Gu D., Wang M., Zhang Z., Chen J. Lack of association between the hOGG1 Ser326Cys polymorphism and breast cancer risk: evidence from 11 case-control studies. Breast Cancer Res Treat 2010, 122:527-531.
21. Cai Q., Shu X.O., Wen W., Courtney R., Dai Q., Gao Y.T., et al. Functional Ser326Cys polymorphism in the hOGG1 gene is not associated with breast cancer risk. Cancer Epidemiol Biomarkers Prev 2006, 15:403-404.
22. Choi J.Y., Hamajima N., Tajima K., Yoo K.Y., Yoon K.S., Park S.K., et al. hOGG1 Ser326Cys polymorphism and breast cancer risk among Asian women. Breast Cancer Res Treat 2003, 79:59-62.
23. Liu C.J., Hsia T.C., Tsai R.Y., Sun S.S., Wang C.H., Lin C.C., et al. The joint effect of hOGG1 single nucleotide polymorphism and smoking habit on lung cancer in Taiwan. Anticancer Res 2010, 30:4141-4145.
24. Park J., Chen L., Tockman M.S., Elahi A., Lazarus P. The human 8-oxoguanine DNA N-glycosylase 1 (hOGG1) DNA repair enzyme and its association with lung cancer risk. Pharmacogenetics 2004, 14:103-109.
25. Yuan W., Xu L., Feng Y., Yang Y., Chen W., Wang J., et al. The hOGG1 Ser326Cys polymorphism and breast cancer risk: a meta-analysis. Breast Cancer Res Treat 2010, 122:835-842.
26. Sun C., Liu X., Zhang H., Guo W., Cai Z., Chen H., et al. Functional polymorphism of hOGG1 gene is associated with type 2 diabetes mellitus in Chinese population. Mol Cell Endocrinol 2010, 325:128-134.
27. Chen X., Wang J., Guo W., Liu X., Sun C., Cai Z., et al. Two functional variations in 5'-UTR of hoGG1 gene associated with the risk of breast cancer in Chinese. Breast Cancer Res Treat 2011, 127:795-803.
28. Chen X., Liu X., Wang J., Guo W., Sun C., Cai Z., et al. Functional polymorphisms of the hOGG1 gene confer risk to type 2 epithelial ovarian cancer in Chinese. Int J Gynecol Cancer 2011, 21:1407-1413.
29. Liu X., Xiao N., Guo W., Wu Y., Cai Z., He Q., et al. The hOGG1 gene 5'-UTR variant c.-53G>C contributes to the risk of gastric cancer but not colorectal cancer in the Chinese population: the functional variation of hOGG1 for gastric cancer risk. JCancer Res Clin Oncol 2011, 137:1477-1485.
30. Elston C.W., Ellis I.O. Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology 1991, 19:403-410.
31. Wolff A.C., Hammond M.E., Schwartz J.N., Hagerty K.L., Allred D.C., Cote R.J., et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. Arch Pathol Lab Med 2007, 131:18-43.
32. Meindl A., Ditsch N., Kast K., Rhiem K., Schmutzler R.K. Hereditary breast and ovarian cancer: new genes, new treatments, new concepts. Dtsch Arztebl Int 2011, 108:323-330.
33. Wooster R., Bignell G., Lancaster J., Swift S., Seal S., Mangion J., et al. Identification of the breast cancer susceptibility gene BRCA2. Nature 1995, 378:789-792.
34. Miki Y., Swensen J., Shattuck-Eidens D., Futreal P.A., Harshman K., Tavtigian S., et al. Astrong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science 1994, 266:66-71.
35. Khoo U.S., Ozcelik H., Cheung A.N., Chow L.W., Ngan H.Y., Done S.J., et al. Somatic mutations in the BRCA1 gene in Chinese sporadic breast and ovarian cancer. Oncogene 1999, 18:4643-4646.
36. Mavaddat N., Pharoah P.D., Blows F., Driver K.E., Provenzano E., Thompson D., et al. Familial relative risks for breast cancer by pathological subtype: a population-based cohort study. Breast Cancer Res 2010, 12:R10.
37. Thompson D., Easton D. The genetic epidemiology of breast cancer genes. JMammary Gland Biol Neoplasia 2004, 9:221-236.
38. Zhang B., Beeghly-Fadiel A., Long J., Zheng W. Genetic variants associated with breast-cancer risk: comprehensive research synopsis, meta-analysis, and epidemiological evidence. Lancet Oncol 2011, 12:477-488.
39. Martrat G., Maxwell C.M., Tominaga E., Porta-de-la-Riva M., Bonifaci N., Gomez-Baldo L., et al. Exploring the link between MORF4L1 and risk of breast cancer. Breast Cancer Res 2011, 13:R40.
40. Shuen A.Y., Foulkes W.D. Inherited mutations in breast cancer genes - risk and response. JMammary Gland Biol Neoplasia 2011, 16:3-15.
41. Edwards B.K., Howe H.L., Ries L.A., Thun M.J., Rosenberg H.M., Yancik R., et al. Annual report to the nation on the status of cancer, 1973-1999, featuring implications of age and aging on U.S. cancer burden. Cancer 2002, 94:2766-2792.
42. Benz C.C., Yau C. Ageing, oxidative stress and cancer: paradigms in parallax. Nat Rev Cancer 2008, 8:875-879.
43. Maynard S., Schurman S.H., Harboe C., de Souza-Pinto N.C., Bohr V.A. Base excision repair of oxidative DNA damage and association with cancer and aging. Carcinogenesis 2009, 30:2-10.
44. Wilson D.M., Bohr V.A. The mechanics of base excision repair, and its relationship to aging and disease. DNA Repair (Amst) 2007, 6:544-559.
45. Kohno T., Shinmura K., Tosaka M., Tani M., Kim S.R., Sugimura H., et al. Genetic polymorphisms and alternative splicing of the hOGG1 gene, that is involved in the repair of 8-hydroxyguanine in damaged DNA. Oncogene 1998, 16:3219-3225.
46. Hill J.W., Evans M.K. Dimerization and opposite base-dependent catalytic impairment of polymorphic S326C OGG1 glycosylase. Nucl Acids Res 2006, 34:1620-1632.
47. Metzger-Filho O., Tutt A., de Azambuja E., Saini K.S., Viale G., Loi S., et al. Dissecting the heterogeneity of triple-negative breast cancer. JClin Oncol 2012, 30:1879-1887.
48. Alexander B.M., Sprott K., Farrow D.A., Wang X., D'Andrea A.D., Schnitt S.J., et al. DNA repair protein biomarkers associated with time to recurrence in triple-negative breast cancer. Clin Cancer Res 2010, 16:5796-5804.
49. Lee E., McKean-Cowdin R., Ma H., Spicer D.V., Van Den Berg D., Bernstein L., et al. Characteristics of triple-negative breast cancer in patients with a BRCA1 mutation: results from a population-based study of young women. JClin Oncol 2011, 29:4373-4380.
50. Alli E., Sharma V.B., Sunderesakumar P., Ford J.M. Defective repair of oxidative DNA damage in triple-negative breast cancer confers sensitivity to inhibition of poly(ADP-ribose) polymerase. Cancer Res 2009, 69:3589-3596.
51. Saha T., Rih J.K., Roy R., Ballal R., Rosen E.M. Transcriptional regulation of the base excision repair pathway by BRCA1. JBiol Chem 2010, 285:19092-19105.
52. Karihtala P., Kauppila S., Puistola U., Jukkola-Vuorinen A. Absence of the DNA repair enzyme human 8-oxoguanine glycosylase is associated with an aggressive breast cancer phenotype. Br J Cancer 2012, 106:344-347.
53. Halazonetis T.D., Gorgoulis V.G., Bartek J. An oncogene-induced DNA damage model for cancer development. Science 2008, 319:1352-1355.
54. Hamann I., Konig C., Richter C., Jahnke G., Hartwig A. Impact of cadmium on hOGG1 and APE1 as a function of the cellular p53 status. Mutat Res 2011.
55. Chatterjee A., Mambo E., Osada M., Upadhyay S., Sidransky D. The effect of p53-RNAi and p53 knockout on human 8-oxoguanine DNA glycosylase (hOGG1) activity. FASEB J 2006, 20:112-114.
56. Lakhani S.R., Van De Vijver M.J., Jacquemier J., Anderson T.J., Osin P.P., McGuffog L., et al. The pathology of familial breast cancer: predictive value of immunohistochemical markers estrogen receptor, progesterone receptor, HER-2, and p53 in patients with mutations in BRCA1 and BRCA2. JClin Oncol 2002, 20:2310-2318.